• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4642681)   Today's Articles (2624)   Subscriber (50524)
For: Dos Santos JBR, da Silva MRR, Almeida AM, Acurcio FDA, Alvares-Teodoro J. Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Rev Pharmacoecon Outcomes Res 2020;21:1011-1016. [DOI: 10.1080/14737167.2021.1840980] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Number Cited by Other Article(s)
1
Ding Q, Shiltz D, Hossami D, Konieczny AM. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. Expert Rev Pharmacoecon Outcomes Res 2022;22:1231-1241. [PMID: 36004551 DOI: 10.1080/14737167.2022.2117690] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
2
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BIOMED RESEARCH INTERNATIONAL 2021;2021:4450162. [PMID: 34877355 PMCID: PMC8645365 DOI: 10.1155/2021/4450162] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 10/05/2021] [Accepted: 11/08/2021] [Indexed: 12/26/2022]
3
Moraes FA, da Silva MRR, Dos Santos JBR, Acurcio FA, Almeida AM, Kakehasi AM, Alvares-Teodoro J. Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value Health Reg Issues 2021;26:135-141. [PMID: 34390960 DOI: 10.1016/j.vhri.2021.06.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Revised: 05/05/2021] [Accepted: 06/14/2021] [Indexed: 01/22/2023]
4
da Silva MRR, Dos Santos JBR, Almeida AM, Alvares-Teodoro J, Acurcio FDA. Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Rev Pharmacoecon Outcomes Res 2021;22:473-479. [PMID: 33474995 DOI: 10.1080/14737167.2021.1880325] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA